Vivos Therapeutics, Inc. (VVOS) Earnings Call Transcripts

Vivos Therapeutics, Inc.'s Latest Earnings Call - Q1 FY2026

In the first quarter of 2026, Vivos Therapeutics, Inc. (VVOS) reported a significant revenue increase of 70% year-over-year, reaching $5.1 million, driven primarily by enhanced sleep testing services and treatment options for obstructive sleep apnea (OSA). Despite this growth, the company faced rising operational costs, leading to a net cash usage of approximately $6 million. Management remains optimistic about future revenue growth, citing a strategic pivot towards partnerships with sleep centers and a focus on expanding their service offerings, including a pediatric program expected to generate revenue by July 2026.

Reported metrics

Guidance from management

Management expects to see gradual improvements in profit margins by the end of 2026, driven by established teams and increased provider efficiency. They also anticipate revenue growth from new initiatives in insomnia treatment and pediatric programs.

What management said

Yes, that's a great question. I would say it's more of a ramp than a step function. And I would say that we are -- our forecasts project that we will be in places where we have established teams and established providers, we expect to see that -- those profit margins realized by the end of this year. So within this calendar year, we expect to see it -- see those margins gradually improve and increase until we get t...

What analysts pressed on

Analysts expressed concerns regarding the sustainability of revenue growth amidst rising operational costs and the need for additional financing. There were questions about the relevance of deferred revenue from VIP enrollments, which management indicated is minimal and will be recognized by year-end.

Main topics on the call

• Revenue Growth Acceleration — Vivos achieved a 70% increase in revenue year-over-year, totaling $5.1 million in Q1 2026, compared to $3 million in Q1 2025. Management noted, "Our confidence has been validated with a 34% revenue increase quarter-over-...
• Cost Management Challenges — Despite revenue growth, costs increased significantly, with general and administrative expenses rising to $9 million, up from $4.9 million in the prior year. This was attributed to costs associated with the Sleep Center ...
• Strategic Pivot to Sleep Centers — The acquisition of the Sleep Center of Nevada is central to Vivos' strategy, allowing for increased patient appointments and service offerings. Management emphasized that the pivot is taking hold, with completed patient ...
• Future Growth Initiatives — Management outlined plans to expand clinical services to insomnia and other sleep disorders, which could add $2,000 to $3,000 per patient. Additionally, a pediatric program is expected to generate revenue starting in Jul...

Read the full Vivos Therapeutics, Inc. transcript (Q1 FY2026) → Summary generated from the call transcript; every figure above is stated by management on the record.

Earnings Call History

EarningsCalls.dev has 25 Vivos Therapeutics, Inc. earnings call transcripts on record, spanning May 17, 2021 to May 20, 2026. Based on this history, Vivos Therapeutics, Inc. reports quarterly. The most recent call on file is dated May 20, 2026. The full list is below — each row opens the complete, free-to-read transcript.

Ticker

VVOS

Exchange

NasdaqCM

Country

US

Sector

Health Care

Industry

Health Care Providers and Services

Calls on record

25

First call

May 17, 2021

Most recent

May 20, 2026

Reporting cadence

quarterly